Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product revenue of $202.1M in Q4 and $677.6M for FY25 was in line with the pre-announcement and exceeded its prior estimates, reflecting continued expansion in prescriber breadth and depth alongside longer duration of therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KNSA:
